In honor of the 15-year anniversary of the founding of the Clinical Data Interchange Standards Consortium (CDISC) and the recently approved CDISC status as a 501(c)(3) charitable foundation, the Annual Report for year 2011 has been released and is available for download on the CDISC website.
In honor of the 15 year anniversary of the founding of the Clinical Data Interchange Standards Consortium (CDISC) and the recently approved CDISC status as a 501(c)(3) charitable foundation, the Annual Report for year 2011 has been released and is available for download on the CDISC website.
Key successes CDISC has had over the past 15 years are displayed graphically in a two-page timeline detailing major achievements since the organization’s founding in 1997. The report includes the mission and vision of CDISC, milestones for year 2011, and information about CDISC-certified education. Trends in CDISC membership and current leadership information are also detailed. Fascinating insight is given in the Annual Report to the rapid growth and productivity of CDISC since its beginnings as a strictly volunteer organization.
Readers also have the opportunity to get a closer look at where CDISC is heading over the next three years, through the inclusion of the CDISC Strategic Goals for 2012-15. The CDISC Board of Directors has been focused on delineating this new set of Strategic Goals since its Annual Meeting in 2011, and these were officially launched in January 2012. In summary, these five goals focus on: 1) supporting data aggregation and secondary use of research data; 2) enabling interoperability between clinical care and clinical research; 3) developing CDISC SHARE (shared health and research electronic library); 4) expediting the development of new therapeutic area standards to augment the CDISC foundational standards to support the needs of researchers and the FDA; and, 5) leveraging our global, nonprofit, vendor neutral, independent status to forge productive collaborations with and ensure value for key stakeholder communities.
“CDISC prides itself on doing its utmost to provide understandable, transparent information about the operational activities of the organization,” stated Dr. Rebecca Kush, CDISC President and CEO. “This first public Annual Report is a major accomplishment for CDISC, displaying the incredible effort and dedication of a multitude of members, volunteers and CDISC staff, who have worked around the world for 15 years to make CDISC what it is today-the common language for clinical research.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.